# Space bioeconomy

Orbital protein-crystallization and pharmaceutical manufacturing exploiting microgravity to grow structures unattainable on Earth, dedicated re-entry capsules returning drug candidates and tissue products to ground, and bioregenerative life-support systems recycling resources for long-duration missions — the applied space-biomanufacturing layer distinct from terrestrial bioproduction equipment covered elsewhere on this platform.

Source: https://en.bioecon.ru/technology/space-bioeconomy/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: NASA in-space biomanufacturing partnership program + ISS National Laboratory commercial research access | OECD: Biopharmaceuticals, Industrial biotechnology | Regulator: FDA (USA), FAA (USA)]

The space bioeconomy applies microgravity conditions to biomanufacturing processes
that are physically constrained on Earth by gravity-driven convection and
sedimentation. The field spans four distinct activities: orbital protein
crystallization and pharmaceutical development that exploits microgravity to grow
larger, more ordered crystal structures than gravity permits terrestrially;
dedicated re-entry capsule manufacturing that returns drug candidates, cancer
therapeutics, and other biological products from orbit to ground facilities;
space-based manufacturing of protein-based medical devices, such as artificial
retinas, that benefit from microgravity's uniform, defect-free layer deposition; and
bioregenerative life-support research that integrates in-situ resource utilization
with biological systems to recycle water, air, and nutrients for long-duration
missions. One orbital manufacturer completed on-orbit operations for a cancer
therapeutic and other pharmaceutical investigations launched to the International
Space Station, while another startup signed a collaboration deal with a major US
pharmaceutical firm specifically to develop drugs using microgravity-enabled
manufacturing. A protein-based artificial-retina developer has expanded its
commercial low-Earth-orbit manufacturing strategy beyond the ISS to commercial space
stations under development. The category is distinct from terrestrial bioproduction
equipment — bioreactors, purification systems, cleanroom facilities — covered
elsewhere on this platform: space bioeconomy is specifically biomanufacturing that
depends on the microgravity environment itself as a production input, not
Earth-based equipment adapted for other uses.

The key directions of the space bioeconomy are:
1. **Orbital protein crystallization and drug development:** microgravity conditions
   allow protein crystals to grow larger and more ordered than gravity-bound
   crystallization permits, supporting pharmaceutical development investigations
   including cancer therapeutics conducted aboard the International Space Station.
2. **In-space pharmaceutical manufacturing partnerships:** dedicated orbital
   manufacturing platforms partner directly with pharmaceutical companies to develop
   drugs using microgravity-enabled processes, with product batches returned to
   Earth via purpose-built re-entry capsules.
3. **Space-manufactured protein-based medical devices:** microgravity's uniform,
   sedimentation-free environment benefits the layer-by-layer deposition process used
   to manufacture protein-based devices such as artificial retinas, expanding
   production from the ISS to commercial space stations.
4. **Bioregenerative life-support systems:** research integrates in-situ resource
   utilization with biological recycling systems to sustain water, air, and nutrient
   loops for long-duration crewed missions beyond low Earth orbit.

### Sectoral value chain

```
[Biological payload preparation] ──> [Orbital launch] ──> [Microgravity bioprocessing]
                                                                    │
                                                          (crystal/tissue/protein growth)
                                                                    │
                                                                    ▼
[Ground-based validation/scaling] <─── [Re-entry capsule recovery] <─── [On-orbit product harvest]
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Biological payload preparation** | A protein, cell line, or biological sample is prepared and packaged for launch to an orbital platform. | **In:** biological material, launch-qualified packaging. **Out:** flight-ready biological payload. |
| **Orbital launch** | The payload is launched to the International Space Station or a commercial orbital platform. | **In:** flight-ready biological payload, launch vehicle. **Out:** payload in orbit. |
| **Microgravity bioprocessing** | The biological material undergoes crystallization, cell culture, or layer deposition under microgravity conditions unattainable on Earth. | **In:** payload in orbit, microgravity environment. **Out:** processed biological product (crystal, tissue, protein structure). |
| **On-orbit product harvest** | The processed biological product is collected and prepared for return to Earth. | **In:** processed biological product. **Out:** harvested, return-ready product. |
| **Re-entry capsule recovery** | A dedicated re-entry capsule returns the harvested product from orbit to a ground recovery site. | **In:** harvested, return-ready product, re-entry capsule. **Out:** recovered product on Earth. |
| **Ground-based validation/scaling** | The recovered product is validated against terrestrial controls and assessed for pharmaceutical or device development scaling. | **In:** recovered product on Earth. **Out:** validated product ready for further development. |

Cross-cutting technologies of the sector:
- **Microgravity protein crystallization:** the absence of gravity-driven convection
  and sedimentation allows protein crystals to grow larger and more ordered than
  terrestrial crystallization permits, supporting structural drug-development
  research.
- **Orbital pharmaceutical manufacturing:** dedicated orbital platforms and re-entry
  capsules enable direct pharmaceutical company partnerships to develop and return
  drug candidates produced under microgravity conditions.
- **Bioregenerative life-support systems:** integrated in-situ resource utilization
  and biological recycling systems sustain water, air, and nutrient loops for
  long-duration space missions.

---

## US

The US hosts an orbital biomanufacturing platform operator running pharmaceutical
investigations aboard the space station, a re-entry-capsule pharmaceutical
manufacturing startup partnering directly with major pharma, an orbital habitat
developer, and a protein-based medical-device manufacturer expanding to commercial
space stations.

### orbital pharmaceutical manufacturing, re-entry capsule drug development, protein-based device manufacturing
- **Redwire Space:** completed on-orbit operations for a cancer therapeutic and other
  pharmaceutical investigations launched to the International Space Station, and
  operates a commercial mission program advancing in-space pharmaceutical
  development.
- **Varda Space Industries:** develops medicines in microgravity using dedicated
  re-entry capsules to return product to Earth, and signed a collaboration agreement
  with a major US pharmaceutical firm to advance microgravity-enabled treatments for
  a rare pulmonary disease.
- **Sierra Space:** develops the LIFE orbital habitat platform, positioned within the
  broader in-space manufacturing ecosystem alongside other orbital biomanufacturing
  operators.
- **LambdaVision:** a pre-clinical-stage biotech manufacturing protein-based
  artificial retinas using microgravity's layer-deposition advantages, expanding its
  commercial low-Earth-orbit manufacturing strategy from the ISS to commercial space
  stations under a new agreement.

---

## CN

No China-headquartered space bioeconomy organization cleared this screening round
with confirmed, on-domain evidence.

### screening limitation
- **Screening note:** two candidate China-based space biomanufacturing/space-breeding
  organizations were probed and neither returned confirming, organization-specific
  evidence this round — not asserted as absent, only as unconfirmed; available
  evidence was dominated by generic "commercial space" and "space-breeding" industry
  news rather than company-specific product or program documentation.

---

## EU

France hosts a bioregenerative life-support systems developer researching
biological recycling for long-duration space missions.

### bioregenerative life-support systems
- **Interstellar Lab (France):** researches bioregenerative life-support systems
  integrating in-situ resource utilization with biological recycling, covered in
  peer-reviewed and industry analysis of sustainable space-exploration life-support
  approaches.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Redwire Space** | 🇺🇸 USA | *On-orbit pharmaceutical/cancer therapeutic investigations* | ISS-based commercial biomanufacturing missions | Commercial |
| **Varda Space Industries** | 🇺🇸 USA | *Microgravity drug development, re-entry capsule return* | Direct pharma-company partnership deals | Commercial |
| **Sierra Space** | 🇺🇸 USA | *LIFE orbital habitat platform* | In-space manufacturing ecosystem participant | Commercial |
| **LambdaVision** | 🇺🇸 USA | *Protein-based artificial retina manufacturing* | Microgravity layer-deposition, ISS-to-commercial-station expansion | Pre-clinical biotech |
| **Interstellar Lab** | 🇫🇷 France | *Bioregenerative life-support research* | ISRU-integrated biological recycling systems | Research/commercial |

---

## Tech stack and innovations

The stack layers microgravity-exploiting bioprocessing, dedicated orbital-to-ground
logistics, and biological life-support recycling on a common space-biomanufacturing
backbone.

1. **Microgravity-exploiting bioprocessing:**
   - The absence of gravity-driven convection and sedimentation allows protein
     crystals to grow larger and more ordered, and enables uniform, defect-free
     layer deposition for protein-based device manufacturing, both physically
     unattainable at terrestrial scale.
   - This capability is the core value proposition of the entire sector: a physical
     production advantage that exists only in the microgravity environment itself.
2. **Dedicated orbital-to-ground product logistics:**
   - Purpose-built re-entry capsules return biological products — drug candidates,
     therapeutic investigations — from orbital manufacturing platforms to ground
     recovery and validation facilities.
   - This capability closes the loop between orbital production and terrestrial
     pharmaceutical development pipelines, without which orbital manufacturing
     advantages could not reach a commercial drug-development process.
3. **Bioregenerative life-support integration:**
   - Research integrates in-situ resource utilization with biological recycling
     systems to sustain water, air, and nutrient loops independent of resupply,
     targeting long-duration missions beyond low Earth orbit.
   - This capability addresses a distinct problem from product manufacturing —
     sustaining crew life support — using overlapping biological-systems expertise.

---

## Value chains and production pipelines

### Industrial pipeline of orbital biomanufacturing (NASA in-space biomanufacturing partnership program / ISS National Laboratory access)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Biological payload       │ ───> │ 2. Orbital launch              │
│    preparation              │      │                                  │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. On-orbit product         │ <─── │ 3. Microgravity                │
│    harvest                  │      │    bioprocessing                │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Re-entry capsule         │ ───> │ 6. Ground-based                │
│    recovery                 │      │    validation/scaling           │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Biological payload preparation
A protein, cell line, or biological sample is prepared and packaged for launch to an
orbital platform.

#### Stage 2: Orbital launch
The payload is launched to the International Space Station or a commercial orbital
platform.

#### Stage 3: Microgravity bioprocessing
The biological material undergoes crystallization, cell culture, or layer deposition
under microgravity conditions unattainable on Earth.

#### Stage 4: On-orbit product harvest
The processed biological product is collected and prepared for return to Earth.

#### Stage 5: Re-entry capsule recovery
A dedicated re-entry capsule returns the harvested product from orbit to a ground
recovery site.

#### Stage 6: Ground-based validation/scaling
The recovered product is validated against terrestrial controls and assessed for
pharmaceutical or device development scaling.

---